$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance
Key Takeaways Atea Pharmaceuticals, Inc. (ATAI) reported Q4 2025 revenue of $125 million, surpassing analyst consensus of $118 million, per the company’s earnings call presentation. Non-GAAP diluted earnings per share (EPS) reached $0.15, exceeding expectations of $0.10, according to internal company financial statements. The company initiated a Phase 3 clinical trial for its novel antiviral […]
$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance Read More »

